This HTML5 document contains 138 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/chemspider/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/chebi/
n16http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/pharmgkb/
n7http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/pubchem-compound/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/kegg-drug/
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/drugbank/
n28http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n3http://linked.opendata.cz/ontology/drugbank/
n29http://www.drugs.com/cdi/
n14http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00581/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00581
rdf:type
n3:Drug
n3:description
A synthetic disaccharide used in the treatment of constipation and hepatic encephalopathy. It has also been used in the diagnosis of gastrointestinal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p887)
n3:dosage
n9:271B4E11-363D-11E5-9242-09173F13E4C5 n9:271B4E12-363D-11E5-9242-09173F13E4C5 n9:271B4E0D-363D-11E5-9242-09173F13E4C5 n9:271B4E0E-363D-11E5-9242-09173F13E4C5 n9:271B4E0F-363D-11E5-9242-09173F13E4C5 n9:271B4E10-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
1.7-2 hours
n3:indication
For the treatment of constipation and hepatic encephalopathy.
n3:manufacturer
n4:271B4DF1-363D-11E5-9242-09173F13E4C5 n4:271B4DF5-363D-11E5-9242-09173F13E4C5 n4:271B4DEF-363D-11E5-9242-09173F13E4C5 n4:271B4DF0-363D-11E5-9242-09173F13E4C5 n4:271B4DF8-363D-11E5-9242-09173F13E4C5 n4:271B4DF9-363D-11E5-9242-09173F13E4C5 n4:271B4DF6-363D-11E5-9242-09173F13E4C5 n4:271B4DF7-363D-11E5-9242-09173F13E4C5 n4:271B4DFC-363D-11E5-9242-09173F13E4C5 n4:271B4DFD-363D-11E5-9242-09173F13E4C5 n4:271B4DFA-363D-11E5-9242-09173F13E4C5 n4:271B4DFB-363D-11E5-9242-09173F13E4C5 n4:271B4DFE-363D-11E5-9242-09173F13E4C5 n4:271B4DF2-363D-11E5-9242-09173F13E4C5 n4:271B4DF3-363D-11E5-9242-09173F13E4C5 n4:271B4DF4-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00581 n26:DB00581
dcterms:title
Lactulose
adms:identifier
n11:PA164748762 n12:Lactulose n18:10856 n19:DB00581 n20:6359 n21:D00352 n22:0054-8486-16 n23:C07064 n24:46506757 n25:11333
n3:mechanismOfAction
Lactulose is a synthetic sugar used in the treatment of constipation and liver disease. It consists of the monosaccharides fructose and galactose. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of via evolved-beta galactosidase from colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool. In treating heptic diseases (hepatic encephalopathy) it is thought that lactulose draws out ammonia from the body in the same way that it draws out water into the colon.
n3:packager
n4:271B4DE9-363D-11E5-9242-09173F13E4C5 n4:271B4DEA-363D-11E5-9242-09173F13E4C5 n4:271B4DE7-363D-11E5-9242-09173F13E4C5 n4:271B4DE8-363D-11E5-9242-09173F13E4C5 n4:271B4DE5-363D-11E5-9242-09173F13E4C5 n4:271B4DE6-363D-11E5-9242-09173F13E4C5 n4:271B4DE3-363D-11E5-9242-09173F13E4C5 n4:271B4DE4-363D-11E5-9242-09173F13E4C5 n4:271B4DE1-363D-11E5-9242-09173F13E4C5 n4:271B4DE2-363D-11E5-9242-09173F13E4C5 n4:271B4DDF-363D-11E5-9242-09173F13E4C5 n4:271B4DE0-363D-11E5-9242-09173F13E4C5 n4:271B4DDD-363D-11E5-9242-09173F13E4C5 n4:271B4DDE-363D-11E5-9242-09173F13E4C5 n4:271B4DDB-363D-11E5-9242-09173F13E4C5 n4:271B4DDC-363D-11E5-9242-09173F13E4C5 n4:271B4DD9-363D-11E5-9242-09173F13E4C5 n4:271B4DDA-363D-11E5-9242-09173F13E4C5 n4:271B4DD7-363D-11E5-9242-09173F13E4C5 n4:271B4DD8-363D-11E5-9242-09173F13E4C5 n4:271B4DD3-363D-11E5-9242-09173F13E4C5 n4:271B4DD6-363D-11E5-9242-09173F13E4C5 n4:271B4DD4-363D-11E5-9242-09173F13E4C5 n4:271B4DD1-363D-11E5-9242-09173F13E4C5 n4:271B4DD2-363D-11E5-9242-09173F13E4C5 n4:271B4DD5-363D-11E5-9242-09173F13E4C5 n4:271B4DCF-363D-11E5-9242-09173F13E4C5 n4:271B4DD0-363D-11E5-9242-09173F13E4C5 n4:271B4DCD-363D-11E5-9242-09173F13E4C5 n4:271B4DCE-363D-11E5-9242-09173F13E4C5 n4:271B4DCB-363D-11E5-9242-09173F13E4C5 n4:271B4DCC-363D-11E5-9242-09173F13E4C5 n4:271B4DED-363D-11E5-9242-09173F13E4C5 n4:271B4DEE-363D-11E5-9242-09173F13E4C5 n4:271B4DEB-363D-11E5-9242-09173F13E4C5 n4:271B4DEC-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The primary route of elimination is fecal. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.
n3:synonym
Lactulosa 4-O-beta-D-Galactopyranosyl-D-fructose Lactulosum 4-O-beta-D-Galactopyranosyl-D-fructofuranose Lactulose
n3:toxicity
LD<sub>50</sub>=18.2 g/kg (oral, rat). Side effects include diarrhea and resultant dehydration.
n15:hasAHFSCode
n16:40-10-00
n3:foodInteraction
Take without regard to meals. Drink liberally.
n3:synthesisReference
Renato Carobbi, Franco Innocenti, "Process for preparing high-purity lactulose syrup and the syrup obtained." U.S. Patent US4978397, issued April, 1961.
foaf:page
n14:lactulose.htm n28:lac_0300.shtml n29:lactulose-crystals.html
n3:IUPAC-Name
n5:271B4E17-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4E1D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4E1C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4E19-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4E1A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4E1B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4E2D-363D-11E5-9242-09173F13E4C5 n5:271B4E15-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4E16-363D-11E5-9242-09173F13E4C5 n5:271B4E2F-363D-11E5-9242-09173F13E4C5 n5:271B4E13-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4E14-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n17:A06AD11
n3:H-Bond-Acceptor-Count
n5:271B4E23-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4E24-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4E1E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4E1F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4E21-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4E20-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4E22-363D-11E5-9242-09173F13E4C5
n3:absorption
Poorly absorbed from the gastrointestinal tract as no human enzyme that is capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
4618-18-2
n3:category
n3:containedIn
n8:271B4E0B-363D-11E5-9242-09173F13E4C5 n8:271B4E0C-363D-11E5-9242-09173F13E4C5 n8:271B4E09-363D-11E5-9242-09173F13E4C5 n8:271B4E0A-363D-11E5-9242-09173F13E4C5 n8:271B4E07-363D-11E5-9242-09173F13E4C5 n8:271B4E08-363D-11E5-9242-09173F13E4C5 n8:271B4E05-363D-11E5-9242-09173F13E4C5 n8:271B4E06-363D-11E5-9242-09173F13E4C5 n8:271B4E03-363D-11E5-9242-09173F13E4C5 n8:271B4E04-363D-11E5-9242-09173F13E4C5 n8:271B4E01-363D-11E5-9242-09173F13E4C5 n8:271B4E02-363D-11E5-9242-09173F13E4C5 n8:271B4DFF-363D-11E5-9242-09173F13E4C5 n8:271B4E00-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4E29-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4E2B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4E2C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4E2E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4E28-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4E27-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4E2A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4E18-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4E25-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4E26-363D-11E5-9242-09173F13E4C5